These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35194118)

  • 1. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.
    Amintas S; Fernandez B; Chauvet A; Chiche L; Laurent C; Belleannée G; Marty M; Buscail E; Dabernat S
    Sci Rep; 2022 Feb; 12(1):2976. PubMed ID: 35194118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma.
    Kim SJ; Kim MJ; Han JS; Sung YN; An S; Lee JH; Song KB; Hwang DW; Lee SS; Cho H; Kim SC; Eshleman JR; Hong SM
    Pancreas; 2019 Mar; 48(3):400-411. PubMed ID: 30747828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.
    Leick KM; Tomanek-Chalkley A; Coleman KL; Chan CHF
    Ann Surg Oncol; 2023 Oct; 30(11):6652-6660. PubMed ID: 37303025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
    Baechmann S; Ormanns S; Haas M; Kruger S; Remold A; Modest DP; Kirchner T; Jung A; Werner J; Heinemann V; Boeck S
    BMC Cancer; 2017 May; 17(1):374. PubMed ID: 28549417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
    Nitschke C; Markmann B; Walter P; Badbaran A; Tölle M; Kropidlowski J; Belloum Y; Goetz MR; Bardenhagen J; Stern L; Tintelnot J; Schönlein M; Sinn M; van der Leest P; Simon R; Heumann A; Izbicki JR; Pantel K; Wikman H; Uzunoglu FG
    Clin Chem; 2023 Mar; 69(3):295-307. PubMed ID: 36644936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance.
    Miglio U; Oldani A; Mezzapelle R; Veggiani C; Paganotti A; Garavoglia M; Boldorini R
    Pathol Res Pract; 2014 May; 210(5):307-11. PubMed ID: 24629489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
    Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.
    Buscail L; Bournet B; Cordelier P
    Nat Rev Gastroenterol Hepatol; 2020 Mar; 17(3):153-168. PubMed ID: 32005945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
    Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease.
    Turrini O; Gilabert M; Ewald J; Moutardier V; Delpero JR; Iovanna JL
    J Visc Surg; 2017 Oct; 154(5):329-333. PubMed ID: 28844705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer.
    Nauheim D; Moskal D; Renslo B; Chadwick M; Jiang W; Yeo CJ; Nevler A; Bowne W; Lavu H
    J Surg Oncol; 2022 Aug; 126(2):314-321. PubMed ID: 35333412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
    Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
    Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
    Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
    Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
    Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Shen H; Lundy J; Strickland AH; Harris M; Swan M; Desmond C; Jenkins BJ; Croagh D
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.